Cost-Effectiveness Analysis of Percutaneous Sclerotherapy for Venous Malformations

详细信息    查看全文

• 作者：Yusuke Ono ; MD^a ; ^{y-ono@radiol.med.osaka-u.ac.jp" class="auth_mail" title="E-mail the corresponding author} ; Keigo Osuga ; MD ; PhD^a ; Tomoyuki Takura ; MEng ; PhD^b ; Masahisa Nakamura ; MD ; PhD^a ; Kentaro Shibamoto ; MD ; PhD^c ; Akira Yamamoto ; MD ; PhD^d ; Hiroyasu Fujiwara ; MD ; PhD^e ; Hidefumi Mimura ; MD ; PhD^f ; Noriyuki Tomiyama ; MD ; PhD^a
• 关键词：EQ-5D ; EuroQol-5 Dimension ; ICER ; incremental cost-effectiveness ratio ; QALY ; quality-adjusted life year ; QOL ; quality of life ; SF-36 ; Short-Form 36 ; VM ; venous malformation
• 刊名：Journal of Vascular and Interventional Radiology
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：27
• 期：6
• 页码：831-837
• 全文大小：596 K

文摘

To assess cost-effectiveness of sclerotherapy for venous malformations (VMs) to improve patient quality of life (QOL).

Materials and Methods

This prospective study enrolled 28 patients with symptomatic VMs who underwent sclerotherapy. EuroQol-5 Dimension (EQ-5D) and Short-Form 36 (SF-36) Health Survey were used to measure health-related QOL. Questionnaires were collected before and 1, 3, 6, and 12 months after sclerotherapy. Quality-adjusted life years (QALYs) were calculated using EQ-5D score as a measure of health utility. Medical costs obtained from the hospital accounting system and other costs of staff, drugs, materials, and angiographic equipment were calculated for each procedure. Cost-effectiveness was analyzed using incremental cost-effectiveness ratio (ICER) as the medical cost/gain of QALYs.

Results

Median EQ-5D scores improved from 0.768 (range, 0.705–1) to 1 (range, 0.768–1) after 6 months (P = .023) and 1 (range, 0.768–1) after 12 months (P = .063). The gain of QALYs at 12 months was 0.043. The mean medical cost was ¥281,228 ($2,337). The pain group (baseline bodily pain scale of SF-36 score < 70) showed greater improvement in median EQ-5D score, from 0.705 (range, 0.661–0.768) to 0.768 (range, 0.705–1) after 6 months (P = .041) and 0.768 (range, 0.768–1) after 12 months (P = .049). ICER at 12 months was ¥6,600,483 ($54,840) in the overall group and decreased to ¥3,998,113 ($33,218) in the pain group, < ¥6,000,000 ($49,850), threshold for acceptance of a public health benefit in Japan, even accounting for 50% increase in costs.

Conclusions

Sclerotherapy was cost-effective for improving QOL for symptomatic VMs, especially for patients with moderate to severe pain.